- Price
- $16.39
- Day
- +3.21%
- Mkt Cap
- $1.73B
- 52W Range
- $14.68 – $25.32
- Volume
- 2.85M
- Beta
- 0.20
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 28, 2026, that were previously approved by its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as amended, as a material inducement to employment to Michael Severino, M.D. as Chief Executive Officer of Sarepta. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). Dr. Se.
Read full article
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read full article
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta's Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transiti.
Read full article
Sarepta Therapeutics said on Monday it appointed former Tessera Therapeutics CEO Michael Severino its chief executive, effective July 28. The longtime AbbVie executive, will succeed Doug Ingram.
Read full article
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, Aug. 5, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss these results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentati.
Read full article
Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD therapy that could challenge Exondys 51 if approved.
Read full article